



**PHARMACY
VISION
20/20**

CSHP SEMINAR 20 • OCTOBER 21-25
Disneyland
RESORT

INTERDISCIPLINARY APPROACH TO PAIN MANAGEMENT IN AN OLDER ADULT IN THE MIDST OF AN OPIOID CRISIS AND COVID -19

TATYANA GURVICH, PHARM.D., BCGP

ASSISTANT PROFESSOR OF CLINICAL PHARMACY

USC SCHOOL OF PHARMACY

ADJUNCT ASSISTANT PROFESSOR OF FAMILY MEDICINE/GERIATRICS

UCI MEDICAL CENTER

“THIS PROJECT IS/WAS SUPPORTED BY THE HEALTH RESOURCES AND SERVICES ADMINISTRATION (HRSA) OF THE U.S. DEPARTMENT OF HEALTH AND HUMAN SERVICES (HHS) UNDER GRANT NUMBER U1QHP28740, GERIATRICS WORKFORCE ENHANCEMENT PROGRAM FOR \$2.5 MILLION. THIS INFORMATION OR CONTENT AND CONCLUSIONS ARE THOSE OF THE AUTHOR AND SHOULD NOT BE CONSTRUED AS THE OFFICIAL POSITION OR POLICY OR, NOR SHOULD ANY ENDORSEMENTS BE INFERRED BY, HRSA, HHS OR THE U.S. GOVERNMENT.”





DISCLOSURE

Dr. Gurvich has no conflicts of interest

LEARNING OBJECTIVES

- Review the history of the opioid epidemic in the United States.
- Understand the complexities of older adult pain management.
- Review how to build an interprofessional team to manage older adult pain.
- Articulate physical and occupational therapy's role in the interprofessional team treating older adult pain.
- Review of pharmacologic strategies for older adult pain management.
- Participants will be able to develop a customized treatment plan for older adults in pain.

1950's-1980's:
A multidisciplinary
approach

1990's:
Pain is the 5th
Vital Sign

2000's:
DEA's Balanced
Policy

2010-2015:
OPIOID
CRISIS!!

- John Bonica, MD
- Hospital- and clinic-based programs with physicians, psychologists, PT/OT.
- Narcotics were **used sparingly**
- Problems with insurance coverage emerge...
- “Pain is whatever the patient says it is”
- “Treatment of Pain is a **Universal Right**” - WHO
- Cancer pain/terminal care pain management guidelines
- Long-acting medicines like Oxycontin emerge...
- JCAHO mandates pain assessment and treatment

THE NUMBERS BEHIND THE OPIOID CRISIS

- **20%** of patients with chronic pain have received an opioid Rx from their PCP
- **259 million prescriptions** for opioids written in 2012...
Enough for every adult in the United States to have a bottle of pills



2. Dowell D, Haegerich T, Chou R (2016)


THE OPIOID CRISIS AND SENIORS

- Over **500,000 seniors** received opioids in doses higher than recommended by the manufacturer in 2016
- Older adults who misuse opioids **WILL DOUBLE FROM 2004 TO 2020**



3. Substance Abuse and Mental Health Services Administration (2017)

Risk of continued opioid use increases at 4-5 days




Source: Centers for Disease Control and Prevention
Credit: Sarah Frostenson

HOW MUCH IS TOO MUCH?

4. S. Frostenson (2017)

WE'RE GETTING (*SLIGHTLY*) BETTER

Annual opioid prescribing rates overall and for high-dosage prescriptions (≥ 90 MME/day), USA



DISCLAIMER: TARGET OF THE CDC Guidelines for Pain Management

TARGETED PROVIDERS/PATIENTS

- PCP's and Chronic pain patients
 - **NOT Cancer Pain, Palliative Care, Sickle Cell disease**



6. Dowell, Haegerich & Chou (2019)

7. Sinha, Bakshi, Ross & Krishnamurti (2019)

UNINTENDED CONSEQUENCES

- Inflexible interpretation of dosage and treatment duration limits
- Inappropriately abrupt tapering leading to withdrawal and drug seeking behavior
- Application of guidelines to the “wrong patients”
- Chronic pain patients already on large doses of narcotics

Patients are having problems getting prescriptions filled

- Insurance plans only cover a 7-day supply
 - PA's required for additional amounts
- Pharmacies dispense a 7-day supply
 - Schedule II prescriptions are having to be re-written
- Diagnosis codes are being required on Rx's
- Discrepancies in fill dates causing rejected prescriptions





COVID Pandemic and Opioids Misuse: A Pandemic within a Pandemic





Increased risk for adverse outcomes

- ✓ Comorbidity with pulmonary vulnerabilities
- ✓ Opioid effect on the brain stem
- ✓ Triage bias
- ✓ Increased risk of spread
- ✓ Comorbidity of mental health disorders
- ✓ Resource reallocation

DEA Response 3/2020

- ✓ Patient centered care
- ✓ Expanded access to Opioid associated services Telehealth
- ✓ Suspended Drug screening
- ✓ Extended supply for Methadone






CHRONIC PAIN

- 1 in 7 patients report widespread or localized pain lasting 3 months (2)
- 43% of US adults experience chronic musculoskeletal pain (OA, RA, chronic neck or back pain) and/or frequent severe headaches (2)
- 50% of older Americans suffer from chronic pain due to: (9)
 - Arthritis
 - Fibromyalgia
 - Neuropathic pain
 - Chronic back pain
 - Other chronic musculoskeletal disorders

2. Dowell D, Haegerich T, Chou R (2016)

9. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K (2001)

WHAT KIND OF PAIN DO OLDER ADULTS HAVE?



11. American Geriatrics Society (AGS) Panel on Persistent Pain in Older Persons (2002)

HOW DO WE RECOGNIZE PAIN IN THE ELDERLY?

Restlessness,
repetitive
movements

Poor sleep or
appetite

Sad or anxious
or aggravated

Change in
mood or
behavior

Loss of interest
or socialization

Resisting care

Change in ADL

Weight loss

Change in range
of motion or
function

Geriatric-specific Considerations

- **Comorbidities**, including pre-existing respiratory disease
- **Polypharmacy**
- Increased risk of **side effects and drug interactions**
- Reduced **renal function**
- Reduced **therapeutic window**
- Increased **fall risk**
- **Elder abuse (taking or withholding medications)**
- Cognitive changes leading to **medication errors**

TEAM APPROACH TO EFFECTIVE PAIN MANAGEMENT



Physician



Psychologist/Social Worker

Help with pain contract/CBT



PT/OT

Improve Daily Function



Clinical Pharmacist

Improve medication management

Effective Non-Pharmacologic Options

Cognitive Behavioral Therapy (2)

- Behavioral techniques modify situational factors/cognitive processes that exacerbate pain
- Positive effects on disability and catastrophic thinking

Exercise, manipulation, massage, acupuncture (2, 12, 13)

- Reduce pain for chronic low back pain, hip and knee OA, and fibromyalgia
- Improve pain severity, physical function, quality of life.
- Acupuncture: chronic musculoskeletal and OA pain, headache
- Treatment effects persist over time

Multidisciplinary therapies (2, 14)

- Reduce pain and improve function more effectively than single modalities

Building your Team

Early Physical Therapy: (15)

- 88,000 patients, patients with early physical therapy 10% reduction in opioid use

Clinical Pharmacy Intervention: (16)

- 100 patients hospitalized showed improved pain control with clinical pharmacy intervention
- Improved function (sleep, mobility, appetite) seen in 86.6% of patients

Occupational Therapy Intervention: (17)

- Study of 45 patients shows significant improvements in function, pain, and QOL with Lifestyle Redesign
- Patients w/ chronic LBP receiving multidisciplinary biopsychosocial rehabilitation experience less pain and disability
- Positive influence on work status

15. Sun et al., (2018)

16. Mathew, Chamberlain, Alvarez, Alvarez & Shah, (2016)

17. Uyeshiro Simon & Collins, (2017)

What is occupational therapy?

ASHLEY HALLE, OTD, OTR/L
ASSOCIATE PROFESSOR OF CLINICAL
OCCUPATIONAL THERAPY
COORDINATOR OF PRIMARY CARE
RESIDENCY & SERVICES



Occupational therapists help people across the lifespan participate in the things they want and need to do through the therapeutic use of everyday activities (**occupations**). *American Occupational Therapy Association (AOTA)*


“Occupational therapy is the only profession with explicitly focused training on participation in everyday life”

“Healthy everyday activity is an insurance policy against decline” *Florence Clark (19)*



What do occupational therapists *do*?

- Health promotion and lifestyle modification
- Mental and behavioral health management
- Pain management
- Safety and falls prevention



20. Halle, Mroz, Fogelberg & Leland (2018);

21. Metzler et al., (2012);

23. Devereaux & Walker, (1995)

18. AOTA.org;

22. Law, Cooper, Strong, Stewart, Rigby, & Letts, (1996);

The Extraordinary and the Ordinary

ADL s

- Grooming
- Dressing
- Showering / bathing
- In and out of chairs
- In and out of bed
- Feeding and eating


IADLs

- Preparing meals
- Grocery shopping
- Cleaning / yard work
- Driving / community mobility
- Taking medications
- Managing finances

And the FUN things!!

Addressing the Case: Evaluation

- Occupational profile
 - ADLs & IADLs
 - Sleep
 - Education
 - Work
 - Leisure
 - Social participation
- Medical and therapy history
- Development of a plan of care



OT Interventions for Pain Management

Sleep hygiene & positioning	Eating routines	Exercise routines	Adaptive equipment	Compensatory strategies
Body mechanics training	Ergonomics	Relaxation training	Coping skills	Flare-up planning
Activity pacing	Fatigue mgmt.; energy conservation	Community access	Transportation training	Medication routines
	Work accommodations	Home evaluations	Sensory strategies	

**Slide used with permission from Lindsey Reeves, OTD, OTR/L*

Lydia In, PT, DPT, MSPT

Instructor of Clinical Physical Therapy

APTA Board Certified Geriatric Clinical Specialist

APTA Board Certified Oncologic Clinical Specialist



Who are Physical Therapists?

- Physical Therapists (PTs) are movement experts who improve quality of life through prescribed exercise, hands-on care, and patient education.
- PTs examine, evaluate, and treat patients whose conditions limit their ability to move and function in daily life. The overall goal is to maintain, restore, or improve your mobility and help reduce your pain.
- PTs create personalized treatment plans that help their patients improve mobility, manage pain and other chronic conditions, recover from injury and prevent future injury and chronic disease.

MYTHS ABOUT PHYSICAL THERAPY

- “I need a referral to see a physical therapist.”
- “Physical therapy is painful.”
- “Physical therapy is only for injuries and accidents.”
- “Any healthcare professional can perform physical therapy.”
- “Physical therapy isn’t covered by insurance.”
- “Surgery is my only option.”
- “I can do physical therapy myself.”


PATIENTS SHOULD CHOOSE PHYSICAL THERAPY WHEN...

- Patients want to do more than mask the pain.
- Pain/function problems due to low back pain, knee OA or fibromyalgia.
- Synergistic approach is needed with pharmacotherapy.
- Pain lasts 90 days.

PT PAIN ASSESSMENT AND MANAGEMENT

Assess:


- Goals of the patient
- Patient's pain state (e.g., using standard forms (31))
- Gait evaluation and Gait speed
- Functional activities: Getting up from a lying position or in/out of a chair, 5 rep sit to stand, grip strength, Time to Up and Go (TUG), Balance
- Body Mechanics: Bending and lifting
- Home/work environment, health habits and activity level



Develop and Prescribe:

- Exercise program (29)
- Special equipment requirements





Pharmacotherapy Options

WHO ANALGESIC LADDER APPLIES TO ELDERLY

Step 1: Mild to Moderate Pain
(1-3/10)

Non-drug
Non-opioid
+/- adjuvant

Step 2: Moderate Pain
(3-6/10)

Non-drug
Non-opioid
+/- adjuvant
+/- opioids

Step 3: Moderate to Severe Pain
(7-10/10)

Non-drug
Non-opioid
+/- adjuvant
+/- opioids
+ ablative
procedures

2019 AGS BEERS CRITERIA: CONCERNS WITH ADJUVANTS

- **All NSAIDs** are on the Beers list due to GI/CV risk
- Avoid NSAIDs in patients with symptomatic CHF and use cautiously in patients with asymptomatic CHF
- Other potential risk:
 - Increase blood pressure
 - Cause acute kidney injury
 - Increase risk of GI bleeding/PUD in those >75 y.o. with prolonged use
 - Be mindful of concomitant use of anti-platelet drugs/steroids/anticoagulants
- Indomethacin and Ketorolac (Special Mention)

2019 AGS BEERS CRITERIA: CONCERNS WITH ADJUVANTS

- **TCA:**

- Amitriptyline, Imipramine, Nortriptyline, Desipramine, Doxepin
- Anticholinergic side effects: risk of confusion, orthostasis, excessive sedation

- **Muscle relaxants:**

- Anticholinergic SE/dizziness/fall risk
- Unclear efficacy at lower doses

- **SSRIs and SNRIs:**

- Increased risk of falls/fractures/hyponatremia
- More side effects at Clcr < 30ml/min

- **Gabapentin and Pregabalin:**

- Sedation, dizziness, falls, edema
- CNS side effects more likely with Clcr < 60ml/min

COMPARISON OF NSAIDs

Agent	Cox -2 Selectivity	GI risk	CV risk
Celecoxib	High	Low	Moderate – High
Etodolac	High	Low	Moderate – High
Meloxicam	High	Low	Moderate
Ibuprofen	Moderate	Low	Moderate – High
Nabumetone	Moderate	Low	Data NA
Salsalate	Data NA	Low	Data NA
Aspirin	Low	Moderate	Low
Naproxen	Low	Moderate - High	Low
Piroxicam	Moderate	High	Low

- **GI** = inflammation, ulceration, bleeding, perforation
- **CV** = ↑ BP, MI, stroke, sodium & fluid retention, CHF exacerbation
- **Renal** = AKI, toxicity
- **All NSAIDs have differences in efficacy and tolerability**

SELECTED ADJUVANT THERAPIES

Drug	Start Dose	Max Dose	Concerns
APAP (Tylenol)	325-500mg Q4H or 500-1000mg Q6H	2-3g/day	Hepatic insufficiency Hx of alcohol abuse Multiple sources
Naproxen (Aleve)	220mg BID	variable	CV risk, HNT, Renal, Antiplatelet, GI
Ibuprofen (Motrin)	200mg BID	variable	
Celecoxib (Celebrex)	100mg QDay	variable	
Meloxicam (Mobic)	7.5mg QDay	variable	

49. Lexicomp(2020)

SELECTED TOPICAL ADJUVANT THERAPIES

Drug		Start Dose	Max Dose	Concerns
Lidocaine	4% Patch	1-3 patches for 12 hrs/day	17-20 grams/day	Rash, skin irritation
	4% Gel/ Cream	Apply to affected area 3-4x/day		
	5% Ointment & Patch	Single application NTE 5g (~6 inches)		
Diclofenac 1% Gel		2-4 grams topically 4x/day (2g = ~1.25 inches)	8 grams/day (upper extremities) 16 grams/day (lower extremities)	Application site reactions
Capsaicin Cream		Thin film to affected area 3-4x/day	No MAX dose	Burning sensation
Misc agents: Camphor oil/ Menthol		Apply liberally		Generally well tolerated

49. Lexicomp(2020)

SELECTED ADJUVANT THERAPIES

Drug	Start Dose	Renal adjustment (based on Clcr)	Concerns
Duloxetine (Cymbalta)	20mg QDay	Avoid Clcr < 30	Increased BP, DDIs Hyponatremia, fall risk
Venlafaxine (Effexor)	37.5mg QDay	Clcr < 30 50% of max dose	
Gabapentin (Neurontin)	100mg QHS	Clcr < 60 Adjust dosage – (see 49)	Tolerability varies; Sedation, dizziness, falls, edema
Pregabalin (Lyrica)	25mg QHS	Clcr < 60 Adjust dosage – (see 49)	

49. Lexicomp(2020)


WHAT ABOUT CANNABIS?




CANNABIS: OBJECTIVE SCIENTIFIC EVIDENCE

To date, objective scientific research is limited

- (JAMA 2015) ... Systematic Review and Meta-analysis:
 - Moderate-quality evidence supporting cannabinoids for chronic pain and spasticity
 - Cannabinoids associated with **increased risk** of short-term AEs
- (Schmerz 2016) Efficacy, Tolerability and Safety... among Adults with Chronic Pain...
 - **Insufficient evidence** for recommendation for **any** cannabinoid preparations for symptom management in patients with chronic pain associated with rheumatic diseases
- (Annals Int Med 2017) Effects of Cannabis Among Adults with Chronic Pain...
 - **Few** methodologically rigorous trials
 - Formulations **may not reflect commercially available product**
 - **Limited applicability** to older, chronically ill populations




Morphine



Codeine.


shutterstock.com • 1306343641



Opioids: Moderate –Severe Pain




hydrocodone



Hydromorphone



Types of Pain and Opioid Use



OPIOID PRESCRIBING GUIDELINES

Determining when to initiate or continue opioids for chronic pain

Establishment of treatment goals; Discussion of risks and benefits of therapy with patients

Non-pharmacologic therapy → nonopioid therapy → opioid therapy

Opioid selection, dosage, duration, follow-up, and discontinuation

Selection of immediate-release vs. extended-release and long-acting opioids

Dosage considerations; Duration of treatment

Considerations for follow-up and discontinuation of opioid therapy

Assessing risk and addressing harms of opioid use

Evaluation of risk factors for opioid-related harms and ways to mitigate patient risk (38)

Review of prescription drug monitoring program (PDMP) data ; Use of urine drug testing

Considerations for co-prescribing benzodiazepines

Arrangement of treatment for opioid use disorder

36. Lehmann SW, Fingerhood M (2018)

2. Dowell D, Haegerich TM, Chou R (2016)

39. <https://www.cdc.gov/drugoverdose/prescribing/guideline.html>

37. Kirschner N, Ginsburg J, Sulmasy LS (2014)

38. Webster LR, Webster RM (2003)

2019 AGS BEERS CRITERIA: CONCERNS WITH OPIOIDS

Avoid opioids:

History of falls/fractures

With Benzodiazepines or Gabapentinoids

Increased risk of **ataxia, impaired psychomotor function, syncope, & additional falls.**

If opioids are used:

Consider reducing use of other **CNS-active medications** that increase risk of falls and/or overdose

Avoid using the opioid with **more than 2** other CNS-active drugs

Implement strategies to reduce fall risk

Opioid Equivalency Table

Opioid Agent	Milligrams of Opioid per Day Equaling 50 Morphine Equivalents (MEM)	Morphine Equivalents (MEM)	Ratio of Morphine to Other Opioids
Fentanyl transdermal	25 mcg/hr = 0.6 mg/day	50 mg	80:100:1
Hydromorphone/Dilaudid	10 mg	50 mg	5:1
Oxymorphone/Opana	17 mg	50 mg	3:1
Oxycodone/Roxicodone	33 mg	50 mg	1.5:1
Hydrocodone	50 mg	50 mg	1:1
Tramadol/ Ultram	500 mg	50 mg	1:10
Codeine	500 mg	50 mg	1:10

Dosages at or above 50 MME/day increase risks for overdose by at least

2x



the risk at
<20
MME/day.

CDC provides an opioid conversion app, with guidelines and other information:
41. <https://www.cdc.gov/drugoverdose/prescribing/app.html>

What About Tramadol?

- ACR and AAOS recommend Tramadol for OA (47, 48)
 - Weak Mu agonist/5HT-NE reuptake inhibitor
 - SE: Hyponatremia, CNS side effects, seizures with CrCl < 30ml/min, risk of serotonin syndrome
- But... March 2019 JAMA study shows increased all-cause mortality with Tramadol vs. NSAIDs at 1-year follow-up on 11.1M pts over 15 years (42)
 - Risk was not statistically significantly different than codeine

A Tramadol vs naproxen



47. Kolasinski SL, et. Al (2020) 48. American Academy of Orthopaedic Surgeons (2013)
 42. Zeng, Dubreuil, LaRoche, et al. (2019)

METHADONE: NOT RECOMMENDED

Associated with disproportionate numbers of overdose deaths relative to prescribing frequency

Risk of QT prolongation

Methadone: The only naturally long-acting opioid

Difficult to dose: Conversion ratios are dose dependent

2. Dowell D, Haegerich T, Chou R (2016)

Methadone Conversion Table

<i>CURRENT DAILY ORAL MORPHINE EQUIVALENT DOSE</i>	<i>CONVERSION RATIO (MORPHINE TO METHADONE)</i>	<i>CONVERSION FACTOR (APPROXIMATE PERCENTAGE OF MORPHINE DOSE)</i>
≤ 100 mg	3 to 1	33.3
101 to 300 mg	5 to 1	20.0
301 to 600 mg	10 to 1	10.0
601 to 800 mg	12 to 1	8.3
801 to 1,000 mg	15 to 1	6.7
≥1,001 mg	20 to 1	5.0

43. Toombs JD, Kral LA, (2005)

Morphine Equivalent Conversion

Methadone	Conversion factor
1-20mg	4
21-40mg	8
41-60mg	10
61-80mg	12

44. www.cdc.gov (2020)

Prescription of Long-Acting Opioids and Mortality in Patients With Chronic Noncancer Pain

Wayne A. Ray, PhD; Cecilia P. Chung, MD, MPH; Katherine T. Murray, MD; Kathi Hall, BS; C. Michael Stein, MB, ChB

- Prescription of LA opioids for chronic noncancer pain vs. alternative medications increased risk of all-cause mortality
 - **1.64x greater risk of mortality** of LA opioids than adjunctive analgesic anticonvulsant (gabapentin) or low-dose tricyclic antidepressant (amitriptyline)
 - 1.90x greater risk of **out-of-hospital deaths** (most being cardiovascular deaths)
 - Increased risk confined to **first 180 days** of prescribed therapy (even for LA opioid doses of ≤ 60 MME)
- **Study excluded patients ≥ 75 years old**

USING LONG-ACTING WITH SHORT-ACTING NARCOTICS

May be necessary in certain situations when ATC analgesia is necessary when alternatives are ineffective or not tolerated

Long acting agents are used on a schedule

- SR or ER formulations BID-TID schedule
- Patch 72-48 hrs

Short acting are used for breakthrough

- Breakthrough dose is 10-20% of the total daily dose of the ER formulation

When switching between narcotics, back-off by at least 20%

Safe Prescribing Practices

START

- Start at ~25% to 50% adult dose
- **IR NOT ER**
- Limit duration of therapy for acute pain to ≤ 3 days

ADJUST

- Reassess 1-4 weeks after start/dose change or every 3 months for continued therapy
- Benefits vs. risks when ≥ 50 MME/day
- Avoid ≥ 90 MME/day if possible

STOP

- Taper down dose by 10%
- Every week - every month
- Once at lowest dose possible \rightarrow extend interval

Side Effects & How to Mitigate

Side Effect	How to Mitigate
Constipation	Chronic Stimulant laxatives + ↑ fiber intake & hydration, ↑ physical activity, stool softeners
Dry Mouth	Chronic Practice regular dental hygiene, have regular dental visits May recommend oral rinses, ice cubes, drinking water
Nausea/Vomiting	Usually transient (2-3 days) Antiemetic can be used as necessary Consider switching to another opioid
Drowsiness	Usually transient following opioid initiation/dose ↑ Avoid drinking alcohol, operating heavy machinery, or driving
Confusion	Usually transient following opioid initiation/dose ↑

RISKS ASSOCIATED WITH OPIOID USE

HIGHLIGHTED ITEMS ARE ESPECIALLY IMPORTANT FOR GERIATRICS

- **Physical side effects** : Mood changes, drowsiness, **confusion**, nausea, constipation, **urination difficulties**, depressed breathing, itching, osteoporosis
- **Sexual difficulties**: Men and women
- **Physical dependence and risk of withdrawal**: Abdominal cramping, pain, diarrhea, sweating, irritability
- **Tolerance**: Medication changed/DC
- **Addiction** common with personal/family history but can occur in anyone. Drug craving, loss of control, and poor outcomes of use
- **Hyperalgesia**: Increased sensitivity to pain requires change or DC.
- **Overdose or** using with alcohol or other drugs results in respiratory depression, coma, brain damage, death
- **Sleep apnea** caused or worsened by opioids.
- **Victimization**: Risk of theft, deceit, assault, or abuse by persons seeking to obtain opioids for purposes of misuse.
- **Life-threatening irregular heartbeat** with methadone, EKG monitoring required
- **Driving under the influence of drugs**: Opioids at initiation of therapy or with changes in dose

RISK OF OPIOID OVERDOSE

- History of substance/
polysubstance abuse
- Comorbid mental disorders
- Higher prescribed doses of opioid
medications (**>50MME/day**)
- Methadone use
- BZD co-prescribing
- Antidepressant co-prescribing
- Opioid naivety
- Recent opioid abstinence
- Sleep apnea
- Heart or pulmonary complications

2. Dowell D, Haegerich T, Chou R (2016)

Tools for Prescribing Opioids

- **SET GOALS:** For pain relief and function
- **PLAN:** For stopping opioids if treatment is unsuccessful/ineffective
- **EVALUATE:** Continue opioids only if meaningful improvement in *both* pain AND function is documented
- **TRUST:** A pain contract should be signed by the patient and provider
 - Risks and realistic benefits of opioid therapy
 - Patient AND provider responsibilities for managing this therapy
- **VERIFY:**
 - A pain diary may be helpful in assessing use of short-acting opioids
 - Be aware of “Red Flag” behaviors
 - Run a CURES report when refilling
 - Urine drug testing when suspicion arises
 - Naloxone use

RED FLAG BEHAVIORS: CONSISTENT AND PREDICTABLE

- Hx of self-medication with rx and illicit drugs
- Altering opioid dosage w/out physician approval
- Requesting refills before scheduled refill date
- Medications lost or stolen
- Using multiple prescribers and pharmacies
- Requesting particular meds claiming others are ineffective
- Using meds to induce somnolence, sedation or euphoria
- Displaying a decrease in functional capacity despite improvements in pain
- Acting entitled, belligerent or victimized
- Circular answers to questions about daily use of narcotics
- Consistently pushing boundaries of Chronic Pain Protocol structure

AT RISK PATIENTS INDICATED FOR PRESCRIBING NALOXONE

1. Higher-dose (>50mg MME/day) opiate rx
2. Any opioid prescription for pain PLUS:
 - a. Rotated from one opioid to another due to possible incomplete cross-tolerance
 - b. Smoker, COPD, emphysema, asthma, sleep apnea, respiratory infection
 - c. Renal dysfunction, hepatic disease, cardiac illness, HIV/AIDS
 - d. Known or suspected concurrent alcohol use
 - e. Concurrent benzodiazepine or other sedative prescription
 - f. Concurrent antidepressant prescription
3. Voluntary request from patient or caregiver
4. Difficulty accessing emergency medical services (distance, remoteness)
5. Receiving emergency medical care involving opioid intoxicant or overdose
6. Suspected history of substance abuse or nonmedical opioid use
7. Methadone or buprenorphine for addiction

2. Dowell D, Haegerich T, Chou R (2016)

Case Presentation: Ms J.

Carolyn Kaloostian MD MPH
Associate Professor of Clinical Family
Medicine/Geriatrics
Keck School of Medicine of USC



Chief Complaint: Neck and back pain

History of Present Illness: Ms. J. is a 78-year old AAF via telemedicine to establish primary care during the COVID-19 pandemic. Recent ER visit due to disorientation when stopped by CHP who noticed she was asleep at the wheel at a stop sign. After an evaluation, she was discharged home and told to follow-up with PCP. **At discharge no medication changes were made.**

Today she reports a few **falls** in her garden and often **forgetting whether she took her medications**. Her medications do not relieve her chronic neck and low back pain and endorses 11/10 pain. She exclaims **“It hurts all over!”**

Past Medical History: Chronic low back pain, obesity, HTN, CAD, **MDD, mild dementia, insomnia, osteoarthritis, asthma, benzodiazepine dependence, opioid dependence, cannabis use**

Past Surgical History: Prior orthopedic and dental procedures. Bilateral cataract surgery.

Family History: Father with Alcoholism. Mother with h/o Depression.

Social History: Recently widowed, she is a smoker, no h/o IV drug use, consumes MJ edibles.

Case presentation (Cont'd)

Telemedicine Physical Exam: Vitals unable to obtain due to COVID -19.

General: Obese female, no acute distress, **flexed forward due to pain, unable to sit for extended period**

Neurologic: Alert & Oriented X 4, sensation and strength grossly intact and symmetric, extraocular movements intact.

Psychologic: Pressured speech, normal volume, circumferential, tearful, **mood depressed**, denies suicidal ideation.

Musculoskeletal: *Inspection:* no skin changes overlying cervical thoracic or lumbar spine, no blisters or ecchymosis.

Palpation: + ttp over paraspinal muscles with palpable lump over right scapula which is firm mobile and slightly tender to touch (performed by patient).

Range Of Motion: decreased at neck and bilateral shoulders with pain on exam.

Extremities: 1+ lower extremity peripheral edema.

Emergency Room Records:

Vitals:

- HR: 65 → 52 → 61 → 73
- BP: 113/77 → 132/63 → 110/53mmHg
- Temp: 98.6 → 98.1
- RR: 11 → 18 → 20
- SpO2: **Hypoxic on admission**
(90% → 100% → 93%)

Renal Function:

- **Clcr: 60 ml/min**

CT Head w/o Contrast: No acute ischemia, noted age related changes

Urinalysis: (-) for bacteria, clear, (-) nitrites

CXR: no infiltrates, effusion, cardiomegaly, or pneumothorax, low lung volumes

Urine Toxicology: (+) **BZD, Opiates, THC**

Case: Medication List

CNS-Active

- Albuterol 90 mcg; 2 puffs Q6H prn wheezing
- APAP 325 mg; 2 tabs Q4H prn pain/fever
- Metoprolol 50 mg; 1 tab BID
- Omeprazole 20 mg; 1 cap BID
- Simvastatin 40 mg; 1 tab QHS
- Clonazepam 0.5 mg; 1 tab QDay
- Donepezil 10 mg; 1 tab QHS
- Escitalopram 20 mg; 1 tab QDay
- Hydroxyzine 10 mg; 1 tab BID
- Oxycodone/APAP 5-325 mg; 1 tab TID
- Pregabalin 100 mg; 1 cap BID
- Trazodone 150 mg; 1 tab QHS
- Zolpidem 10 mg; 1 tab QHS prn insomnia
- Cannabis THC 10mg nightly prn insomnia

Recommendations for Optimizing Therapy

Pain Management	Depression/ Anxiety	Insomnia	Pruritus
<ul style="list-style-type: none">Utilize topical regimens (Lidocaine 4% ointment, Voltaren 1% gel)Add low dose PO NSAID	<ul style="list-style-type: none">Cross-taper escitalopram to either:<ul style="list-style-type: none">Mirtazapine (if insomnia is more significant)Duloxetine (if pain is more significant)D/C clonazepam	<ul style="list-style-type: none">Maximize use of concurrent antidepressants to address insomniaRe-evaluate use/dose of cannabisIf trazodone is effective, continue at same dose<ul style="list-style-type: none">If not effective, start melatoninD/C zolpidem	<ul style="list-style-type: none">D/C hydroxyzineUse 2nd generation antihistamine

Case: Follow Up

Routine redesign

Sleep hygiene

Ergonomics

Energy conservation

Flare up plan

Mental Health

Social relationships

Medication management help

PT intervention

Pain/weight management

Summary: We are making Progress!

- Opioid use is down
- Adjuvants are being used more
 - Dose adjustments are critical
 - Minimize adjuvants poorly tolerated in older adults
- Framework for opioid prescribing can help
- Patient education is critical
- Using a team approach is one way of providing better wholistic care and alleviating provider and patient stress



ASSESSMENT QUESTION 1

- Which of the following statements is true about the CDC guidelines and Opioid Epidemic?
 - a) The 2016 CDC guidelines target all patients receiving opioid prescriptions including palliative care and sickle cell patients
 - b) Because older adults are frail and medically complicated, they were spared from over-prescribing of opioids by their primary care providers
 - c) Team based pain management has been successfully used in the past in the US and is not a novel concept
 - d) Despite efforts to curb opioid prescribing there has been no decline in the use of this class of medications

ANSWER TO QUESTION # 1

- c) Team based pain management has been successfully used in the past in the US and is not a novel concept

ASSESSMENT QUESTION #2

- An 88 yo patient comes into your clinic for a pain assessment. He is accompanied by his son. Pt looks timid, disheveled and smells. When you are interviewing this patient about his pain, you notice that patient isn't able to answer questions easily and often looks towards to son to provide answers. Which of the following is NOT a reasonable assumption:
 - a) Pt may be suffering for cognitive decline and unable to answer questions
 - b) Because this patient is on multiple medications, he may be confused about all the medicines he is taking
 - c) Patient may be overmedicated because he is not able to take care of himself based on his appearance and your interaction with him.
 - d) Patient abuse is NOT an issue because his son took the time to bring him to the office for an assessment

ANSWER TO QUESTION #2

- d) Patient abuse is NOT an issue because his son took the time to bring him to the office for an assessment

ASSESSMENT: QUESTION #3

- Which of the following statements is false?
 - a) OT's help with mental and behavioral health management
 - b) OT's help with medication routine
 - c) Physical Therapists (PTs) are movement experts who improve quality of life through prescribed exercise, hands-on care, and patient education
 - d) A geriatric patient in pain with moderate to severe OA would not be a candidate for PT

ANSWER TO QUESTION # 3

- d) A geriatric patient in pain with moderate to severe OA would not be a candidate for PT

Acknowledgements: THANK YOU

- Carolyn Kaloostian, MD
- Ashley Halle, OTD
- Lydia In, DPT
- Melissa Durham, Pharm.D.
- Ana Barron, Pharm.D.
- Amy Nham, Pharm.D.
- Liana So, Pharm.D.
- Katelyn Swafford, Pharm.D.

REFERENCE LIST

1. JG, Compton P. Providing chronic pain management in the "Fifth Vital Sign" Era: Historical and treatment perspectives on a modern-day medical dilemma. *Drug Alcohol Depend.* 2017 Apr 1;173 Suppl 1:S11-S21.
2. Dowell D, Haegerich T, Chou R. CDC guidelines for Prescribing Opioids for Chronic Pain – United States 2016. Dept. of Health and Human Services. March 2016
3. Substance Abuse and Mental Health Services Administration. “Opioid Use in the Older Adult Population” 2017.
4. S. Frostenson, The risk of a single 5-day opioid prescription, in one chart, <https://www.vox.com/2017/3/18/14954626/one-simple-way-to-curb-opioid-overuse-prescribe-them-for-3-days-or-less>, March 18, 2017. Source to Centers for Disease Control and Prevention
5. Centers for Disease Control and Prevention. 2018 Annual Surveillance Report of Drug-Related Risks and Outcomes — United States. Surveillance Special Report. Centers for Disease Control and Prevention, U.S. Dept of Health and Human Services. Published August 31, 2018.
6. Dowell, Haegerich & Chou, (2019); Dowell D, Haegerich T, Chou R. No shortcuts to safer opioid prescribing. *N Engl J Med.* 2019;380:2285–7.
7. Sinha CB, Bakshi N, Ross D, Krishnamurti L. Management of chronic pain in adults living with sickle cell disease in the era of the opioid epidemic: a qualitative study. *JAMA Netw Open.* 2019;2(5):e194410. doi:10.1001/jamanetworkopen.2019.4410

REFERENCE LIST

8. Slat, S., Thomas, J., & Lagisetty, P. (2020, May 29). Coronavirus disease 2019 and opioid use—A pandemic within and epidemic. *JAMA Health Forum*. Available from <https://jamanetwork-com.ezp3.lib.umn.edu/channels/health-forum/fullarticle/2766790?resultClick=1>
9. Smith BH, Elliott AM, Chambers WA, Smith WC, Hannaford PC, Penny K. The impact of chronic pain in the community. *Fam Pract*. 2001;18(3):292-299. doi:10.1093/fampra/18.3.292
10. Clark, D 'Total pain', disciplinary power and the body in the work of Cicely Saunders, 1958-1967 (1999) *Social Science and Medicine*, 49 (6) , pp. 727-736.
11. American Geriatrics Society (AGS) Panel on Persistent Pain in Older Persons. Clinical practice guidelines: the management of persistent pain in older persons. *J Am Geriatr Soc*. 2002;50(6 Suppl):S205-S224.
12. Geneen LJ, Moore RA, Clarke C, Martin D, Colvin LA, Smith BH. Physical activity and exercise for chronic pain in adults: an overview of Cochrane Reviews. *Cochrane Database of Systematic Reviews* 2017, Issue 4. Art. No.: CD011279. DOI: 10.1002/14651858.CD011279.pub3 ;
13. Vickers AJ, Vertosick EA, Lewith G, MacPherson H, Foster NE, Sherman KJ, et al. Acupuncture for Chronic Pain: Update of an Individual Patient Data Meta-Analysis. *J Pain* 2018;19(5):455-74.
14. Kamper SJ, Apeldoorn AT, Chiarotto A, et al. Multidisciplinary biopsychosocial rehabilitation for chronic low back pain. *Cochrane Database Syst Rev*. 2014;(9):CD000963. Published 2014 Sep 2. doi:10.1002/14651858.CD000963.pub3

REFERENCE LIST

15. Sun E, Moshfegh J, Rishel CA, Cook CE, Goode AP, George SZ. Association of Early Physical Therapy With Long-term Opioid Use Among Opioid-Naive Patients With Musculoskeletal Pain. *JAMA Netw Open*. 2018;1(8):e185909. doi:10.1001/jamanetworkopen.2018.5909
16. Mathew S, Chamberlain C, Alvarez KS, Alvarez CA, Shah M. Impact of a Pharmacy-Led Pain Management Team on Adults in an Academic Medical Center. *Hosp Pharm*. 2016;51(8):639-645. doi:10.1310/hpj5108-639
17. Uyeshiro Simon A, Collins CER. Lifestyle Redesign[®] for Chronic Pain Management: A Retrospective Clinical Efficacy Study. *Am J Occup Ther*. 2017;71(4):7104190040p1-7104190040p7. doi:10.5014/ajot.2017.025502
18. American Occupational Therapy Association (AOTA), What is Occupational Therapy, <https://www.aota.org/Consumers.aspx> (downloaded 8/29/2020)
19. Clark, 2011, personal communication.
20. Halle AD, Mroz TM, Fogelberg DJ, Leland NE. Occupational Therapy and Primary Care: Updates and Trends. *Am J Occup Ther*. 2018;72(3):7203090010p1-7203090010p6. doi:10.5014/ajot.2018.723001
21. Metzler, C. A., Hartmann, K. D., & Lowenthal, L. A. (2012). Defining primary care: Envisioning the roles of occupational therapy. *American Journal of Occupational Therapy*, 66, 266–270.
22. Law, M., Cooper, B., Strong, S., Stewart, D., Rigby, P., & Letts, L. (1996). The Person-Environment-Occupation Model: A Transactive Approach to Occupational Performance. *Canadian Journal of Occupational Therapy*, 63(1), 9–23. <https://doi.org/10.1177/000841749606300103>

REFERENCE LIST

23. Elizabeth B. Devereaux, Robert B. Walker; The Role of Occupational Therapy in Primary Health Care. *Am J Occup Ther* 1995;49(5):391–396. <https://doi.org/10.5014/ajot.49.5.391>
24. Ceri J. Phillips, The Cost and Burden of Chronic Pain, *Rev Pain*. 2009 Jun; 3(1): 2–5.
25. Hesselstrand, M., Samuelsson, K., & Liedberg, G. (2015). Occupational Therapy Interventions in Chronic Pain - A Systematic Review. *Occupational Therapy International*, 22(4), 183-194. doi: 10.1002/oti.1396
26. American Physical Therapy Association, What Physical Therapists Do, <https://www.apta.org/your-career/careers-in-physical-therapy/becoming-a-pt> , June 01, 2020, downloaded 8/29/2020.
27. American Physical Therapy Association. (2020). Retrieved 13 August 2020, from <https://www.apta.org/>
28. Middleton, A., & Fritz, S. (2013). Assessment of Gait, Balance, and Mobility in Older Adults: Considerations for Clinicians. *Current Translational Geriatrics And Experimental Gerontology Reports*, 2(4), 205-214. doi: 10.1007/s13670-013-0057-2
29. <https://www.hep2go.com/>, downloaded 8/29/2020
30. American Physical Therapy Association, <https://www.choosept.com/assets/86175f58-3127-4268-86c3-f4cbd636f6b8/637040478627370000/choosept-handout-painprofile-pdf>, 2019, downloaded 10/1/2020
31. Bijur, P., Silver, W., & Gallagher, E. (2001). Reliability of the Visual Analog Scale for Measurement of Acute Pain. *Academic Emergency Medicine*, 8(12), 1153-1157. doi: 10.1111/j.1553-2712.2001.tb01132.x
32. By the 2019 American Geriatrics Society Beers Criteria® Update Expert Panel. American Geriatrics Society 2019 Updated AGS Beers Criteria® for Potentially Inappropriate Medication Use in Older Adults. *J Am Geriatr Soc*. 2019;67(4):674-694. doi:10.1111/jgs.15767

REFERENCE LIST

33. Cannabinoids for Medical Use: A Systematic Review and Meta-analysis, JAMA 2015; 313 (24): 2456-2473
(<https://jamanetwork.com/journals/jama/fullarticle/2338251>)
34. The Effects of Cannabis Among Adults With Chronic Pain and an Overview of General Harms: A Systematic Review, Annals of Internal Medicine 9/17 Vol 167 No 5 (<https://annals.org/aim/fullarticle/2648595/effects-cannabis-among-adults-chronic-pain-overview-general-harms-systematic>)
35. Efficacy, tolerability and safety of cannabinoids in chronic pain associated with rheumatic diseases (fibromyalgia syndrome, back pain, osteoarthritis, rheumatoid arthritis): A systematic review of randomized controlled trials., Schmerz 2016; 30 (1): 62-88
36. Lehmann SW, Fingerhood M. Substance-use disorders in later life. N Engl J Med 2018;379:2351-2360.
37. Kirschner N, Ginsburg J, Sulmasy LS. Prescription drug abuse: executive summary of a policy position paper from the American College of Physicians. Ann Intern Med 2014;160:198-198.
38. Webster LR, Webster RM. Predicting aberrant behaviors in opioid-treated patients: preliminary validation of the Opioid Risk Tool. Pain Med. 2003;6:432-442
39. <https://www.cdc.gov/drugoverdose/prescribing/guideline.html>
40. https://qioprogram.org/sites/default/files/2019BeersCriteria_JAGS.pdf
41. <https://www.cdc.gov/drugoverdose/prescribing/app.html>
42. Zeng, Dubreuil, LaRochelle, et al. "Association of Tramadol With All-Cause Mortality Among Patients With Osteoarthritis." JAMA. March 2019

REFERENCE LIST

43. Toombs JD, Kral LA. Methadone treatment for pain states. Am Fam Physician. 2005 Apr 1;71(7):1353-8
44. CALCULATING TOTAL DAILY DOSE OF OPIOIDS FOR SAFER DOSAGE, U.S. Dept. of Health and Human Services/Centers for Disease Control and Prevention (CDC), https://www.cdc.gov/drugoverdose/pdf/calculating_total_daily_dose-a.pdf, downloaded 10/4/2020.
45. Wayne A. Ray, PhD; et al. "Prescription of Long Acting Opioids and Mortality in Patients with Chronic Noncancer Pain", JAMA. June 2016
46. Kaye AD, Baluch A, Scott JT. Pain management in the elderly population: a review. Ochsner J. 2010 Fall;10(3):179-87.
47. Kolasinski SL, Neogi T, Hochberg MC, Oatis C, Guyatt G, Block J, Callahan L, Copenhaver C, Dodge C, Felson D, Gellar K, Harvey WF, Hawker G, Herzig E, Kwoh CK, Nelson AE, Samuels J, Scanzello C, White D, Wise B, Altman RD, DiRenzo D, Fontanarosa J, Girardi G, Ishimori M, Misra D, Shah AA, Shmigel AK, Thoma LM, Turgunbaev M, Turner AS, Reston J. 2019 American College of Rheumatology/Arthritis Foundation Guideline for the Management of Osteoarthritis of the Hand, Hip, and Knee. Arthritis Care Res (Hoboken). 2020 Feb;72(2):149-162. doi: 10.1002/acr.24131. Epub 2020 Jan 6
48. American Academy of Orthopaedic Surgeons Treatment of Osteoarthritis of the Knee, Evidence-Based Guideline, 2nd Edition, 2013
https://www5.aaos.org/cc_files/aaosorg/research/guidelines/treatmentofosteoarthritisofthekneeguideline.pdf.
49. Lexicomp, available online with subscription at <http://online.lexi.com>, WoltersKluwer, 2020

SESSION
CODE:



PHARMACY
VISION
20/20

CSHP SEMINAR 20 • OCTOBER 21-25

Disneyland
RESORT